Clinical utility of neurofilament light chain as a biomarker for disease onset and progression in hereditary transthyretin amyloidosis
Serum NfL can be accurately quantified using both ELISA and SIMoA array, and it seems to be a reliable biomarker to detect the transition from presymptomatic to symptomatic disease onset and to monitor disease progression.
Authors
- Mar M. Sánchez (ORCID: https://orcid.org/0000-0001-7701-2892)
- B. Dominguez
- Cristina Borrachero Garro
- Ana Serrano Mira
- Francisco Muñoz Beamud
- A. Sánchez (ORCID: https://orcid.org/0000-0001-6271-7339)
- Araceli Maritza Dávila Macías (ORCID: https://orcid.org/0000-0002-7582-6371)
- Álvaro Gragera-Martínez (ORCID: https://orcid.org/0000-0002-1705-422X)
- Amelia Jiménez Heffernan
- Sandra García (ORCID: https://orcid.org/0000-0003-0093-1123)
Institutions
- Hospital Juan Ramón Jiménez (ES)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2025-10-08
- DOI
- https://doi.org/10.3389/fneur.2025.1660344
- Citations
- 2
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.61